Cerus Corporation Receives IDE Approval to Initiate Phase III ReCePI Study
8 November 2017
Cerus Corporation today announced it has received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate ReCePI (A Randomized, Double-Blinde
